

Kevin Qiwei Zhang MD, PhD



Board certified hospitalist and family medicine practitioner with full license in Massachusetts, New Hampshire, and Wisconsin, I have had extensive clinical and teaching experience in inpatient, critical care, and outpatient practice in the tertiary academic medical centers and community hospitals in multiple states. I obtained PhD in Medical Oncology and Pharmacology at Indiana University School of Medicine with tremendous experience in pharmacology and pharmaceutical research, drug safety and adverse reaction management with more than 20 publications in top-notch medical journals.

CONTACT

kevin.zhang@usbiomedcapital.com

414-687-1768 (Mobile) 617-838-2128 (Office)

CLINICAL, TEACHING AND MEDICAL RESEARCH EXPERIENCE

Physician Mass General Brigham Martha Vineyard Hospital, Martha Vineyard, MA 2021-present

Physician South Shore Hospital, South Weymouth, MA 2018-present

Physician Lahey Medical Center UMass Chan School of Medicine, Burlington, MA 2018-present

Physician Cheshire Medical Center Dartmouth Geisel School of Medicine, Cheshire, NH 2016-2022

Physician Norwood Hospital Norwood, MA 2015-2018

Physician University of Massachusetts Memorial Medical Center UMass Chan School of Medicine, Worcester, MA 2014-2016

Physician Heywood Hospital Gardner, MA 2012-2015

Resident Physician University of Wisconsin Aurora Medical Center, Milwaukee WI 2009-2012

Intern Physician University of Wisconsin Hospital, Madison, WI 2008-2009

Research Fellow Indiana University School of Medicine Dept of Dermatology, Indianapolis, IN 2003-2008

Research Scholar Indiana University Cancer Center / Howard Hughes Institute, Indianapolis, IN 1997-2003

EDUCATION

Ph.D. Medical Oncology and Pharmacology Indiana University School of Medicine 2003

M.D. Tianjin Medical University 1994

BOARD AND LICENSE

American Board of Family Medicine

Full Physician License in Massachusetts, New Hampshire, and Wisconsin

SELECTED AWARDS

Speaker of Class 2012, University of Wisconsin Aurora St Luke Family Medicine Residency

Kligman Dermatology Fellowship American Society for Investigative Dermatology 2007

K. K. Chen Pharmacology Research Scholarship Award 2003

Invitrogen Fellowship for Current Topics in Gene Expression 2002

Excellent Graduate Student Fellowship 2000, 2001

Graduate Education Enhancement Grant 2000

MEMBERSHIP

American Academy of Family Physician

American Society of Hospitalist

American Association of Cancer Research

SELECTED PUBLICATIONS

- Zhang KQ, Al-Hassani M, Travers JB, and Hingtgen CM Role of Platelet-activating factor Receptor in UVB-induced Hyperalgesia *Journal of Investigative Dermatology* 129(1):167-74, 2009
- Zhang KQ, Yao Y, Konger RL, Sinn A, Cai S., Pollok KE, and Travers JB Platelet-activating Factor Mediates Ultraviolet B Radiation-mediated Inhibition of Delayed-Type Contact Hypersensitivity Reactions *Journal of Investigative Dermatology* 128(7):1780-7, 2008
- Zhang KQ, Seltmann H, Zouboulis CC and Travers JB Activation of Platelet-activating Factor Receptor in SZ95 Sebocytes Results in Inflammatory Cytokine and Prostaglandin E2 Production *Experimental Dermatology* 15(10) 769-774, 2006
- Zhang KQ, Seltmann H., Zouboulis CC, and Konger RL Involvement of PPAR-gamma in oxidative stress-mediated prostaglandin E2 production in SZ95 human sebaceous gland cells *Journal of Investigative Dermatology* 126:42-48, 2006
- Zhang KQ, Mousdicas N, Yi Q, Al-Hassani M, Billings S, Howard K, Ishii S, Shimizu T, and Travers JB Staphylococcal Lipoteichoic Acid Inhibits Delay-Type Hypersensitivity Reactions via the Platelet-activating Factor Receptor *Journal of Clinical Investigation* 115:2855-61, 2005
- Zhang KQ, Southall MD, Mezsick SM, Johnson C, Murphy RC, Konger RL, and Travers JB Epidermal Peroxisome Proliferator-activated Receptor γ as a Target for Ultraviolet B Radiation *Journal of Biological Chemistry* 280(1): 73-79, 2005
- Zhang KQ, Ohannesian DW, and Erickson LC Hammerhead Ribozyme-mediated Sensitization of Human Tumor Cells after Treatment with 1,3-Bis(2-chloroethyl)-1-nitrosourea *Journal of Pharmacology and Experimental Therapeutics* 309(2):506-514,2004